Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Teicher

Showing results (11-20 of 417) with videos related to

Pageof 42
Sort By:
Christian Science Monitor (Boston, Mass. : 1983)|October 20, 2001
When minors refuse medical treatmentStacy A Teicher
Biochemical Pharmacology|March 6, 2012
Searching for molecular targets in sarcomaBeverly A Teicher
Hematology/Oncology Clinics of North America|April 1, 1995
Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxiaB A Teicher
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Lonidamine: in vitro/in vivo correlationsB A Teicher
Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology|January 1, 1992
Use of perfluorochemical emulsions in cancer therapyB A Teicher
Current Opinion in Pharmacology|June 16, 2010
Combinations of PARP, hedgehog and HDAC inhibitors with standard drugsBeverly A Teicher
Advances in Experimental Medicine and Biology|April 6, 2006
Hypoxia, tumor endothelium, and targets for therapyBeverly A Teicher
Biochemical Pharmacology|May 12, 2009
Acute and chronic in vivo therapeutic resistanceBeverly A Teicher
Molecular Cancer Therapeutics|March 3, 2019
A Vision from the New Editor-in-ChiefBeverly A Teicher
Oncotarget|March 9, 2019
CD248: A therapeutic target in cancer and fibrotic diseasesBeverly A Teicher
Pageof 42

Showing results (11-20 of 417) with videos related to

Sort By:
Pageof 42
Christian Science Monitor (Boston, Mass. : 1983)|October 20, 2001
When minors refuse medical treatmentStacy A Teicher
Biochemical Pharmacology|March 6, 2012
Searching for molecular targets in sarcomaBeverly A Teicher
Hematology/Oncology Clinics of North America|April 1, 1995
Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxiaB A Teicher
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Lonidamine: in vitro/in vivo correlationsB A Teicher
Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology|January 1, 1992
Use of perfluorochemical emulsions in cancer therapyB A Teicher
Current Opinion in Pharmacology|June 16, 2010
Combinations of PARP, hedgehog and HDAC inhibitors with standard drugsBeverly A Teicher
Advances in Experimental Medicine and Biology|April 6, 2006
Hypoxia, tumor endothelium, and targets for therapyBeverly A Teicher
Biochemical Pharmacology|May 12, 2009
Acute and chronic in vivo therapeutic resistanceBeverly A Teicher
Molecular Cancer Therapeutics|March 3, 2019
A Vision from the New Editor-in-ChiefBeverly A Teicher
Oncotarget|March 9, 2019
CD248: A therapeutic target in cancer and fibrotic diseasesBeverly A Teicher
Pageof 42